Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the national cancer institute: Five-year follow-up report

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 458-465

  Sorensen, J M ^a   Vena, D A ^a   Fallavollita, A ^a   Chun, H G ^a   Cheson, B D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; IMMUNE DEFICIENCY; INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; VOMITING;

EID: 0031036424     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.458     Document Type: Article

References (39)

1. Brockman RW, Schabel JR FM, Montgomery JA: Biologic activity of A-ß-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-ß-D-arabinofurosyladenine. Biochem Pharmacol 26:2193-2196, 1977
2. Plunkett W, Chubb S, Alexander L, et al.: Comparison of the toxicity and metabolism of 9-ß-D-arabinofuranosyl-2-fluoroadenine and 9-ß-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349-2355, 1980
3. Tseng W-C, Derse D, Cheng Y-C, et al.: In vitro biological activity of 9-ß-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol 21:474-477, 1982
4. Parker WB, Bapat AR, Shen JX, et al.: Interaction of 2-halogenated dATP analogs (F, Cl and Br) with human DNA polymerase. DNA primase and ribonucleotide reductase. Mol Pharmacol 34:485-491, 1988
5. Huang P, Chubb S, Plunkett W: Termination of DNA synthesis by 9-ß-D-arabinofuranosyl-2-fluoroadenine. J Biol Chem 265:16617-16625, 1990
6. Robertson LE, Chubb S, Meyn RE, et al.: Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-ß-D-arabinosyl fluoroadenine. Blood 81:143-150, 1993
7. Plunkett W, Gandhi V, Huang P, et al.: Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2-12, 1993 (suppl 7)
8. Brockman RW, Cheng YC, Schabel FM Jr, et al.: Metabolism and chemotherapeutic activity of 9-ß-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence of its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610-3615, 1980
9. White EL, Shaddix SC, Brockman RW, et al.: Comparison of the actions of 9-ß-D-arabinofuranosyl-2-fluoroadenine and 9-ß-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42:2260-2264, 1982
10. Lathan B, Diehl V, Clark GM, et al.: Cytotoxic activity of 9-ß-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system. Eur J Cancer Clin Oncol 24:1891-1895, 1988
11. Hutton JJ, Von Hoff DD, Kuhn J, et al.: Phase I clinical investigation of 9-ß-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44:4183-4186, 1984
12. Warrell RP, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79, 1986
13. Spriggs DR, Stopa E, Mayer RJ, et al.: Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 46:5953-5958, 1986
14. Grever MR, Kopecky KJ, Coltman CA, et al.: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457-459, 1988
15. Fludarabine: June 1995 Annual Report. Bethesda, MD, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Diagnosis and Centers, National Cancer Institute, National Institutes of Health (on file at CTEP)
16. Keating MJ, McLaughlin P, Plunkett W, et al.: Fludarabine -Present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 2:79-83, 1994 (suppl 5)
17. Keating MJ, O'Brien S, Robertson LE, et al.: The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma 2:11-16, 1994 (suppl 14)
18. Keating MJ, O'Brien S, Kantarjian H, et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
19. Sorensen JM, Vena D, Fallavollita A, et al.: Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the group C protocol. Proc Am Soc Clin Oncol 11:264, 1992 (abstr 867)
20. Gale RP, Rai KR (eds): Chronic lymphocytic leukemia: Recent Progress and Future Directions. New York, NY, Alan R. Liss, 1987, pp 253-264
21. MacDonald JS, Haller DG, Mayer RJ, et al. (eds): Manual of Oncologic Therapeutics (ed 3). Philadelphia, PA, Lippincott, 1995, p 525
22. List AF, Kummet TD, Adams JD, et al.: Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 89:388-390, 1991
23. Frame JN, Sorensen JM, Qashu N, et al.: Tumor lysis syndrome (TLS) in patients receiving fludarabine (F) for chronic lymphocytic leukemia (CLL). Proc Am Soc Hematol 82: 1993 (suppl 1, abstr)
24. Cheson BD, Bennett JM, Rai KR, et al.: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29:152-163, 1988
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Hosmer DW, Lemeshow S: Applied Regression Analysis. New York, NY, Wiley, 1989
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
28. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
29. MacDonald JS, Haller DG, Mayer RJ (eds): Manual of Oncologic Therapeutics (ed 3). Philadelphia, PA, Lippincott, 1995, pp 519-523
30. Cheson BD, Vena DA, Foss FM, et al.: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
31. Cone L, Uhr JW: Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J Clin Invest 43:2241-2248, 1964
32. Trump DL, Mann RB, Phelps R, et al.: Richter's syndrome: Diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. Am J Med 68:539-548, 1980
33. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 86:2463-2474, 1995
34. O'Brien S, Kantarjian H, Beran M, et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
35. O'Brien S, del Giglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85:307-318, 1995
36. Rozman C, Monserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057, 1995
37. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995
38. Johnson S, Smith AG, Löffler H, et al.: Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347:1432-1438, 1996
39. Gandhi V, Robertson LE, Keating MJ, et al.: Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34:30-36, 1994